Drug Prices
Biosimilars
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
affordability boards
Learn more about drug pricing
Drug ‘affordability’ boards won’t really help patients
Colorado’s Prescription Drug Affordability Board recently declared that Stelara, a popular treatment for Crohn’s disease and other autoimmune conditions, is “unaffordable.” Soon, the board’s five unelected members could decide whether to impose an “upper payment limit” on the medication. The decision could have significant consequences not just in Colorado but ...
Commentary
Learn more about how price controls hurt consumers
Yet More Evidence That Price Controls Are Bad For Patients
The Democrats’ days in control of federal healthcare policy are numbered. But they were able to do quite a bit of damage during President Biden’s term. The scheme of price controls they’ve put in place for drugs dispensed through Medicare is a case in point. Ten drugs in Medicare Part ...
Biosimilars
The Biosimilar Promise
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater By Wayne Winegarden | October 28, 2024 READ PDF Executive Summary Since 2019, biosimilars have obtained a majority share of most markets where they compete. The combination of lower prices (both biosimilar and originator) and rising market share could ...
Commentary
Learn more about how price fixing stifles innovation
New Schizophrenia Drug Represents Promise Of Pharmaceutical Innovation
Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side ...
Commentary
Learn more about how price controls are driving physician shortages
Price Controls Are Harming Doctors
Whether its pharmaceuticals or health insurance, Vice President Kamala Harris appears to have only one healthcare policy – impose price controls. The untenable financial position of many doctors and private doctor practices due to tightening Medicare reimbursement rates exemplifies the folly of her preferred approach. As I document in a recent ...
Commentary
Harris’s Farcical Price Control Schemes
Karl Marx famously said that history repeats itself first as tragedy, then as farce. Vice President Kamala Harris is bringing that aphorism to life by putting price controls at the center of her economic agenda. Despite centuries of evidence that such controls invariably lead to shortages, rationing and general economic ...
Biosimilars
The Biosimilar Promise
Biosimilars Often Reduce Prices by 50 Percent or More
Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
Commentary
Learn how PBMs pocket savings intended for patients
How Long Can Pharmacy Benefit Managers Go Unchecked?
Last week, a House subcommittee held a hearing on pharmacy benefit managers and their impact on the prices patients pay for prescription drugs. The hearing speaks to voters’ concerns. Republicans and Democrats alike have identified the cost of prescription drugs as their No. 2 health care concern, according to polling ...
Blog
Learn how drug price controls hurt patients, innovation
Senator Sanders’ Price Controls Will Harm Patients
In a patently politicized press release, Senator Bernie Sanders (I-VT) who is Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
Learn more about drug pricing
Drug ‘affordability’ boards won’t really help patients
Colorado’s Prescription Drug Affordability Board recently declared that Stelara, a popular treatment for Crohn’s disease and other autoimmune conditions, is “unaffordable.” Soon, the board’s five unelected members could decide whether to impose an “upper payment limit” on the medication. The decision could have significant consequences not just in Colorado but ...
Learn more about how price controls hurt consumers
Yet More Evidence That Price Controls Are Bad For Patients
The Democrats’ days in control of federal healthcare policy are numbered. But they were able to do quite a bit of damage during President Biden’s term. The scheme of price controls they’ve put in place for drugs dispensed through Medicare is a case in point. Ten drugs in Medicare Part ...
The Biosimilar Promise
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater By Wayne Winegarden | October 28, 2024 READ PDF Executive Summary Since 2019, biosimilars have obtained a majority share of most markets where they compete. The combination of lower prices (both biosimilar and originator) and rising market share could ...
Learn more about how price fixing stifles innovation
New Schizophrenia Drug Represents Promise Of Pharmaceutical Innovation
Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side ...
Learn more about how price controls are driving physician shortages
Price Controls Are Harming Doctors
Whether its pharmaceuticals or health insurance, Vice President Kamala Harris appears to have only one healthcare policy – impose price controls. The untenable financial position of many doctors and private doctor practices due to tightening Medicare reimbursement rates exemplifies the folly of her preferred approach. As I document in a recent ...
Harris’s Farcical Price Control Schemes
Karl Marx famously said that history repeats itself first as tragedy, then as farce. Vice President Kamala Harris is bringing that aphorism to life by putting price controls at the center of her economic agenda. Despite centuries of evidence that such controls invariably lead to shortages, rationing and general economic ...
The Biosimilar Promise
Biosimilars Often Reduce Prices by 50 Percent or More
Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
Learn how PBMs pocket savings intended for patients
How Long Can Pharmacy Benefit Managers Go Unchecked?
Last week, a House subcommittee held a hearing on pharmacy benefit managers and their impact on the prices patients pay for prescription drugs. The hearing speaks to voters’ concerns. Republicans and Democrats alike have identified the cost of prescription drugs as their No. 2 health care concern, according to polling ...
Learn how drug price controls hurt patients, innovation
Senator Sanders’ Price Controls Will Harm Patients
In a patently politicized press release, Senator Bernie Sanders (I-VT) who is Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
